Matches in Nanopublications for { ?s ?p "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- NP283501.RAk7evdzlzW7U7ycLoIY0o_FY89gi3e1exVeY7pgkEvio130_assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP283501.RAk7evdzlzW7U7ycLoIY0o_FY89gi3e1exVeY7pgkEvio130_provenance.
- NP562099.RAFTk8PH0Uq2QqCIpbpCCWArFW5o5tc6e-_KMmJM6z9Bc130_assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP562099.RAFTk8PH0Uq2QqCIpbpCCWArFW5o5tc6e-_KMmJM6z9Bc130_provenance.
- assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP527733.RAi2MrwG8WUoZVggfDAvSztcI5I6XjdveSJdnVOL0vaLE130_assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP527733.RAi2MrwG8WUoZVggfDAvSztcI5I6XjdveSJdnVOL0vaLE130_provenance.
- NP964225.RARWmt4KWj4fnvuBIikGnQ4rzYB9x_ABSBXGykeEZvGb4130_assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP964225.RARWmt4KWj4fnvuBIikGnQ4rzYB9x_ABSBXGykeEZvGb4130_provenance.
- NP964231.RAUKsxTqvLpBnY73nuLAi7eL2u6pBLdkfkTKyKqEqcC4Q130_assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP964231.RAUKsxTqvLpBnY73nuLAi7eL2u6pBLdkfkTKyKqEqcC4Q130_provenance.
- NP801181.RAMDPdwN8LXOwTQxVzAXUc2UHzsQoLvYfTIFgWBf5XKm4130_assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP801181.RAMDPdwN8LXOwTQxVzAXUc2UHzsQoLvYfTIFgWBf5XKm4130_provenance.
- NP964233.RAgmwtwNhd_nSJsGf9rcKuDvUkcEInUaNrK1bPaKT5XNE130_assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP964233.RAgmwtwNhd_nSJsGf9rcKuDvUkcEInUaNrK1bPaKT5XNE130_provenance.
- NP527838.RAKgTfReMSLExWrNcx81hQsiesY4kL9tIdXSmA5iuXVJA130_assertion description "[KRAS mutations were frequent in villous (67%) and tubulovillous (60%) adenomas but were rare or absent in tubular adenomas (6%) and serrated lesions, including hyperplastic polyps, sessile serrated polyps/sessile serrated lesions and traditional serrated adenomas (0-9%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP527838.RAKgTfReMSLExWrNcx81hQsiesY4kL9tIdXSmA5iuXVJA130_provenance.